Abstract # 2758 - Novel Imaging Modalities in Innovative Xenograft Mouse Models of T-Cell Lymphoma Confirm Marked Synergy of Romidepsin and Pralatrexate
Using preclinical, in vivo xenograft tumor models, researchers at Stanford University and Columbia University demonstrated that FOLOTYN, when combined with another PTCL-approved therapy (Romidepsin), showed potential synergistic effects as measured by surface bioluminescence and ultrasound imaging. Ongoing pharmacokinetic and molecular studies are seeking to elucidate the mechanistic basis for the potential synergy in treating patients with PTCL, for whom prognosis still remains poor despite recent advances.
Abstract # 3588 - Phase I Trial of Belinostat and Bortezomib in Patients with Relapsed or Refractory Acute Leukemia, Myelodysplastic Syndrome, or Chronic Myelogenous Leukemia in Blast Crisis - One Year Update
An investigator-sponsored phase 1 study showed that belinostat, when administered with a proteasome inhibitor (bortezomib), was well-tolerated and showed evidence of activity in patients with relapsed or refractory acute leukemia, myelodysplastic syndrome, or chronic myelogenous leukemia in blast crisis. No dose-limiting toxicities have been observed in the study, and no serious adverse events have occurred at an unexpected frequency or severity. There have been 2 partial responses and 1 complete response (out of 22 evaluable patients) in the heavily pretreated population.About Non-Hodgkin's Lymphoma According to the National Cancer Institute ( www.cancer.gov), there are expected to be 70,130 new cases of non-Hodgkin's lymphoma diagnosed and approximately 18,940 deaths in the United States in 2012. Non-Hodgkin's lymphoma is defined as any of a large group of cancers of lymphocytes (white blood cells). Non-Hodgkin's lymphomas can occur at any age and are often marked by lymph nodes that are larger than normal, fever, and weight loss. There are many different types of non-Hodgkin's lymphoma. These types can be divided into aggressive (fast-growing) and indolent or low grade (slow-growing) types, and they can be formed from either B-cells or T-cells. Prognosis and treatment depend on the stage and type of disease. About ZEVALIN® and the ZEVALIN Therapeutic Regimen ZEVALIN (ibritumomab tiuxetan) injection for intravenous use, is indicated for the treatment of patients with relapsed or refractory, low-grade or follicular B-cell non-Hodgkin's lymphoma (NHL). ZEVALIN is also indicated for the treatment of patients with previously untreated follicular non-Hodgkin's Lymphoma who achieve a partial or complete response to first-line chemotherapy.